Geron Co. (NASDAQ:GERN) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Geron Co. (NASDAQ:GERN - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the twelve brokerages that are currently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $5.68.

Several equities analysts have issued reports on the company. B. Riley lowered Geron from a "buy" rating to a "neutral" rating and dropped their price target for the company from $3.50 to $2.00 in a research note on Thursday, February 27th. HC Wainwright downgraded Geron from a "buy" rating to a "neutral" rating in a report on Wednesday, February 26th. Needham & Company LLC decreased their price objective on Geron from $7.00 to $5.00 and set a "buy" rating for the company in a report on Thursday, February 27th. Scotiabank decreased their price objective on Geron from $6.00 to $4.00 and set a "sector outperform" rating for the company in a report on Thursday, February 27th. Finally, Barclays restated an "overweight" rating and set a $4.00 price objective (down previously from $9.00) on shares of Geron in a report on Thursday, February 27th.

Geron Price Performance

Shares of GERN opened at $1.60 on Wednesday. Geron has a 52-week low of $1.46 and a 52-week high of $5.34. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. The business's 50 day moving average price is $2.73 and its two-hundred day moving average price is $3.65. The firm has a market cap of $1.02 billion, a PE ratio of -5.00 and a beta of 0.53.

Remove Ads

Geron (NASDAQ:GERN - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04). Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The firm had revenue of $47.54 million for the quarter, compared to analyst estimates of $45.29 million. On average, equities analysts anticipate that Geron will post -0.25 EPS for the current year.

Institutional Investors Weigh In On Geron

Institutional investors have recently bought and sold shares of the stock. US Bancorp DE grew its stake in Geron by 68.4% in the 3rd quarter. US Bancorp DE now owns 18,296 shares of the biopharmaceutical company's stock valued at $83,000 after purchasing an additional 7,429 shares during the period. Los Angeles Capital Management LLC bought a new position in Geron in the 3rd quarter valued at $178,000. Empowered Funds LLC bought a new position in Geron in the 3rd quarter valued at $67,000. First Turn Management LLC bought a new position in Geron in the 3rd quarter valued at $14,187,000. Finally, Intech Investment Management LLC bought a new position in Geron in the 3rd quarter valued at $1,102,000. Institutional investors own 73.71% of the company's stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.